The Medicines and Healthcare products Regulatory Agency (MHRA) has announced an update to the Summary of Product Characteristics (SPC) for Librela Solution for Injection for Dogs. This product is used to treat pain in dogs.
The updated SPC includes revised information on adverse events, which are potential side effects that may occur when using the product. This change aims to provide healthcare professionals with the most up-to-date information to inform their decisions when treating dogs with Librela Solution for Injection.
According to the European Medicines Agency (EMA), Librela Solution for Injection has been authorised for use in the UK since 2010. The product is manufactured by Dechra Veterinary Products Limited.
The update to the SPC is part of ongoing efforts to ensure that medicines and medical devices available in the UK are safe and effective. This includes regular reviews of product information and labelling to ensure that they remain accurate and up-to-date.
The MHRA has stated that healthcare professionals should consult the updated SPC for the most current information on the use of Librela Solution for Injection for Dogs.